Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein.
暂无分享,去创建一个
J. Berliner | M. Navab | S. Hama | K. Faull | A. Fogelman | A. Watson | B. La Du | B. Du | B. Du | Mohamad Navabt
[1] J. Berliner,et al. Effect of platelet activating factor-acetylhydrolase on the formation and action of minimally oxidized low density lipoprotein. , 1995, The Journal of clinical investigation.
[2] M. Kendall,et al. The oxidation hypothesis of atherosclerosis , 1994, The Lancet.
[3] E. Änggård,et al. Formation of F2‐isoprostanes during aortic endothelial cell‐mediated oxidation of low density lipoprotein , 1994, FEBS letters.
[4] F. Pagani,et al. The protective role of high-density lipoprotein on oxidized-low-density-lipoprotein-induced U937/endothelial cell interactions. , 1994, European journal of biochemistry.
[5] J. Berliner,et al. The role of oxidized low-density lipoprotein in atherogenesis , 1993 .
[6] K. Badr,et al. Vascular smooth muscle actions and receptor interactions of 8-iso-prostaglandin E2, an E2-isoprostane. , 1993, Biochemical and biophysical research communications.
[7] F. Parhami,et al. Minimally modified low density lipoprotein-induced inflammatory responses in endothelial cells are mediated by cyclic adenosine monophosphate. , 1993, The Journal of clinical investigation.
[8] V. Simeon,et al. Heat inactivation of paraoxonase and arylesterase activities in human and rabbit serum. , 1993, Chemico-biological interactions.
[9] D. Steinberg,et al. Role of oxidized low density lipoprotein in atherogenesis. , 1991, The Journal of clinical investigation.
[10] J. Morrow,et al. Effects of a novel prostaglandin, 8-epi-PGF2 alpha, in rabbit lung in situ. , 1992, The American journal of physiology.
[11] G. Zimmerman,et al. The platelet-activating factor acetylhydrolase from human plasma prevents oxidative modification of low-density lipoprotein. , 1992, Transactions of the Association of American Physicians.
[12] A. J. Valente,et al. Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. , 1991, The Journal of clinical investigation.
[13] S. Ratnam,et al. Influence of serum paraoxonase polymorphism on serum lipids and apolipoproteins , 1991, Clinical genetics.
[14] P. Durrington,et al. Paraoxonase prevents accumulation of lipoperoxides in low‐density lipoprotein , 1991, FEBS letters.
[15] D. Stafforini,et al. Human plasma platelet-activating factor acetylhydrolase. Oxidatively fragmented phospholipids as substrates. , 1991, The Journal of biological chemistry.
[16] G. Chisolm,et al. Lipoxygenase-mediated transformation of human low density lipoprotein to an oxidized and cytotoxic complex. , 1991, Journal of lipid research.
[17] A. Smolen,et al. Purification of human serum paraoxonase/arylesterase. Evidence for one esterase catalyzing both activities. , 1991, Drug metabolism and disposition: the biological fate of chemicals.
[18] D. Steinberg,et al. Role of oxidised low density lipoprotein in atherogenesis. , 1993, British heart journal.
[19] A. J. Valente,et al. Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[20] L. Fong,et al. High-density lipoprotein inhibits the oxidative modification of low-density lipoprotein. , 1990, Biochimica et biophysica acta.
[21] M. Territo,et al. Minimally modified low density lipoprotein stimulates monocyte endothelial interactions. , 1990, The Journal of clinical investigation.
[22] A. Lusis,et al. Induction of endothelial cell expression of granulocyte and macrophage colony-stimulating factors by modified low-density lipoproteins , 1990, Nature.
[23] J. Goldstein,et al. Scavenging for receptors , 1990, Nature.
[24] A. Gotlieb,et al. Macrovascular Endothelial Cells from Porcine Aorta , 1990 .
[25] D. Stafforini,et al. Platelet-activating factor acetylhydrolase from human plasma. , 1990, Methods in enzymology.
[26] J L Witztum,et al. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. , 1989, The Journal of clinical investigation.
[27] J L Witztum,et al. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. , 1989, The New England journal of medicine.
[28] G. Zimmerman,et al. An oxidized derivative of phosphatidylcholine is a substrate for the platelet-activating factor acetylhydrolase from human plasma. , 1989, The Journal of biological chemistry.
[29] D. Morel,et al. Superoxide anion participation in human monocyte-mediated oxidation of low-density lipoprotein and conversion of low-density lipoprotein to a cytotoxin. , 1989, Journal of immunology.
[30] J L Witztum,et al. Low density lipoprotein undergoes oxidative modification in vivo. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[31] D. Gordon,et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. , 1989, Circulation.
[32] L. Stevenson,et al. Monocyte migration into the subendothelial space of a coculture of adult human aortic endothelial and smooth muscle cells. , 1988, The Journal of clinical investigation.
[33] M. Territo,et al. Modification of the Recalde method for the isolation of human monocytes. , 1988, Journal of lipid research.
[34] M. Haberland,et al. Malondialdehyde-altered protein occurs in atheroma of Watanabe heritable hyperlipidemic rabbits. , 1988, Science.
[35] C. Walker,et al. Low A-esterase activity in serum of patients with fish-eye disease. , 1987, Clinical chemistry.
[36] D. Steinberg,et al. Macrophage Oxidation of Low Density Lipoprotein Generates a Modified Form Recognized by the Scavenger Receptor , 1986, Arteriosclerosis.
[37] D. Epps,et al. Rapid separation of lipid classes in high yield and purity using bonded phase columns. , 1985, Journal of lipid research.
[38] D. Steinberg,et al. Enhanced Macrophage Degradation of Biologically Modified Low Density Lipoprotein , 1983, Arteriosclerosis.
[39] J. Chemnitius,et al. Organophosphate detoxicating hydrolases in different vertebrate species. , 1983, Comparative biochemistry and physiology. C, Comparative pharmacology and toxicology.
[40] G. Chisolm,et al. LDL-induced cytotoxicity and its inhibition by HDL in human vascular smooth muscle and endothelial cells in culture. , 1979, Atherosclerosis.
[41] M C Hjortland,et al. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. , 1977, The American journal of medicine.
[42] W. J. Dyer,et al. A rapid method of total lipid extraction and purification. , 1959, Canadian journal of biochemistry and physiology.
[43] R. Havel,et al. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. , 1955, The Journal of clinical investigation.
[44] O. H. Lowry,et al. Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.